Soligenix Inc. Reports Promising Results in HyBryte(TM) Trial for Early-Stage Cutaneous T-Cell Lymphoma
Soligenix Inc.'s HyBryte(TM) shows promising treatment success in early-stage cutaneous T-cell lymphoma, offering hope for patients with limited options.
Soligenix Inc. (NASDAQ: SNGX) has announced encouraging interim results from its HyBryte(TM) (synthetic hypericin) program, indicating significant treatment success in early-stage cutaneous T-cell lymphoma (CTCL). The ongoing investigator-initiated study, led by Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program, highlights the potential of HyBryte(TM) as a much-needed alternative for CTCL patients, especially those in the early stages of the disease.
The study, which evaluates extended HyBryte(TM) therapy administered twice weekly for up to 54 weeks in patients with early-stage mycosis fungoides, has shown promising outcomes at the 18-week evaluation point. With no new FDA-approved, skin-directed therapies introduced in over a decade, and conventional treatments carrying significant risks, the success of HyBryte(TM) could mark a pivotal advancement in CTCL care.
For more detailed information on the interim results, visit https://ibn.fm/IUoEe. Investors seeking the latest updates on Soligenix can find more information in the company’s newsroom at https://ibn.fm/SNGX.